Cybin

Cybin presented on 29.06.2026 results for the quarter ended 31.03.2026 and reported a loss per share of 1.28 CAD compared with -1.46 CAD in the year-ago quarter. For the fiscal year a loss per share of 5.88 CAD was reported, after -5.59 CAD in the previous year. The figures were presented at a financial conference. » Altro su finanzen.net

Cybin shares fell 1.9% after announcing an at-the-market (ATM) program to sell up to $100 million of common stock. Sales are to be conducted through Cantor Fitzgerald and Cantor Fitzgerald Canada and will be executed at prevailing market prices. Proceeds are intended for growth initiatives and working capital; the program runs until Oct. 17, 2027, or until all shares are sold. There is no obligation to sell, and all transactions are subject to customary exchange approval conditions. » Altro su de.investing.com

Cybin announces a voluntary transfer from the NYSE American to the Nasdaq Global Market and plans to change its corporate name to Helus Pharma and its ticker from CYBN to HELP; trading on Nasdaq is scheduled to begin on January 5, 2026. The clinically oriented company (market cap $338.85 million) is conducting phase‑3 studies with CYB003 as an adjunctive treatment for major depressive disorders and CYB003 has received Breakthrough Therapy designation. Cybin also reports progress in trials, a new financing round of $175 million, and continued buy recommendations from leading banks despite adjusted price targets. » Altro su de.investing.com